PMID- 38521402
OWN - NLM
STAT- MEDLINE
DCOM- 20240408
LR  - 20240408
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 827
DP  - 2024 Mar 28
TI  - Effects of the designer drug 4-methylamphetamine on core temperature and 
      serotonin levels in the striatum and hippocampus of rats.
PG  - 137740
LID - S0304-3940(24)00117-4 [pii]
LID - 10.1016/j.neulet.2024.137740 [doi]
AB  - New psychoactive substances (NPS) are typically synthesized in clandestine 
      laboratories in an attempt to chemically modify already federally regulated drugs 
      in an effort to circumvent the law. Drugs derived from a phenethylamine 
      pharmacophore, such as 4-chloroamphetamine and 3,4-methylenedioxymethamphetamine 
      (MDMA), reliably induce thermogenesis and serotonergic deficits in the striatum 
      and hippocampus of rodents. 4-methylamphetamine (4-MA), a relative newcomer to 
      the NPS scene, was originally investigated in the mid-1900 s as a potential 
      anorexigenic agent. With its phenethylamine pharmacophore, 4-MA was hypothesized 
      to produce similar toxicological alterations as its chemical analogs. In the 
      present study, three doses (1.0, 2.5, and 5.0 mg/kg, ip.) of 4-MA were 
      administered to rats twice daily for two days. Core temperature data were 
      calculated and analyzed as temperature area under the curve (TAUC). On the second 
      day of dosing, a hypothermic response to 4-MA (2.5 and 5.0 mg/kg) was noted 
      between 0.5 and 2.0 h post-treatment. Only the highest dose of 4-MA decreased 
      body weight on the second day of treatment and maintained this reduction in 
      weight for seven days after treatment ceased. None of the doses of 4-MA evaluated 
      significantly altered serotonin levels in the hippocampus or striatum seven days 
      after final treatment. The present findings demonstrate that the 4-methyl 
      substitution to amphetamine generates a pharmacological and toxicological profile 
      that differs from other similar phenethylamine analogs.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Gilman, T Lee
AU  - Gilman TL
AD  - Department of Psychological Sciences, Brain Health Research Institute, Healthy 
      Communities Research Institute, Kent State University, Kent, OH, 44242, United 
      States.
FAU - Canfield, Jeremy R
AU  - Canfield JR
AD  - The Ohio Attorney General's Center for the Future of Forensic Science, Bowling 
      Green State University, Bowling Green, OH 43403, United States.
FAU - Worst, Travis J
AU  - Worst TJ
AD  - The Ohio Attorney General's Center for the Future of Forensic Science, Bowling 
      Green State University, Bowling Green, OH 43403, United States.
FAU - Sprague, Jon E
AU  - Sprague JE
AD  - The Ohio Attorney General's Center for the Future of Forensic Science, Bowling 
      Green State University, Bowling Green, OH 43403, United States. Electronic 
      address: jesprag@bgsu.edu.
LA  - eng
PT  - Journal Article
DEP - 20240321
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 44RAL3456C (Methamphetamine)
RN  - 9E273KL7HS (1-(4-methylphenyl)propane-2-amine)
RN  - 333DO1RDJY (Serotonin)
RN  - 0 (Designer Drugs)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - CK833KGX7E (Amphetamine)
RN  - 0 (Serotonin Agents)
RN  - 0 (Amphetamines)
SB  - IM
MH  - Rats
MH  - Animals
MH  - *Methamphetamine/pharmacology
MH  - Serotonin/pharmacology
MH  - *Designer Drugs/pharmacology
MH  - Temperature
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/pharmacology
MH  - Amphetamine/pharmacology
MH  - Hippocampus
MH  - Serotonin Agents/pharmacology/analysis
MH  - *Amphetamines
OTO - NOTNLM
OT  - 4-methylamphetamine
OT  - Designer drug
OT  - Hippocampus
OT  - Serotonin
OT  - Striatum
OT  - Thermogenesis
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/03/24 00:42
MHDA- 2024/04/08 06:43
CRDT- 2024/03/23 20:41
PHST- 2024/02/15 00:00 [received]
PHST- 2024/03/19 00:00 [revised]
PHST- 2024/03/20 00:00 [accepted]
PHST- 2024/04/08 06:43 [medline]
PHST- 2024/03/24 00:42 [pubmed]
PHST- 2024/03/23 20:41 [entrez]
AID - S0304-3940(24)00117-4 [pii]
AID - 10.1016/j.neulet.2024.137740 [doi]
PST - ppublish
SO  - Neurosci Lett. 2024 Mar 28;827:137740. doi: 10.1016/j.neulet.2024.137740. Epub 
      2024 Mar 21.